DVAX - Dynavax Pharma Operating income before deduction of amortization

The robotization of biological product production lines reduces manual labor costs, as confirmed by the EBITDA chart. The value of 18.55 characterizes this level of cash flow. Dynavax Technologies (DVAX) capitalization relies on the sale of the Heplisav-B vaccine through pharmacies and clinics. Stable revenue from this product allows the company to effectively control development costs for new adjuvant drugs.

DVAX (Dynavax Technologies Corp) Operating profit EBITDA history from 11/23/2025 to 02/21/2026

Dynavax Technologies Corp (DVAX) - metric breakdowns and financial figures

- stock price and consensus target price:

Price Chart Dynavax|DVAX - Analyst Consensus Forecast

- market capitalization statistics:

Market Capitalization Dynavax|DVAX - Real Price to Acquire Entire Company

- balance sheet equity data:

Net Assets per Single Share Dynavax|DVAX - Book Capitalization|Market-to-Book Ratio dynavax.com|DVAX - Aggregate Company Assets

- company total debt and liquidity indicators:

- net income and valuation multiples indicators:

DVAX - Net Income|Expected Profit Dynavax Technologies|DVAX - P/E Multiple|Forward P/E Multiple dynavax.com|DVAX - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Dynavax|DVAX - Operating profit before deduction of amortization|Earnings per share for the trailing year Dynavax|DVAX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months dynavax.com|DVAX - Earnings growth in current year|Expected net earnings per share growth next year Dynavax Technologies

Fundamental company valuation:Dynavax Technologies

Dynavax Technologies (DVAX) dominates the hepatitis B vaccination segment thanks to Heplisav-B. An analysis of aggregated EBITDA allows for an assessment of the company's actual operational cycle efficiency. This indicator captures the daily cash flow stripped of non-cash expenses, reflecting the fundamental resilience of the business. Growth in this metric confirms successful expansion in the US market and the capitalization of new developments. Comparing current values with historical data warns investors against overpaying if the trend fades.

Competitors of Dynavax Technologies (DVAX)

Arrowhead Corp - Profit before payment of interest, taxes and amortization|Mirum Pharmaceuticals - Operating profit EBITDA|Operating income before deduction of amortization arbutusbio.com ABUS|IVA (Inventiva) - Operating profit before deduction of amortization|GYRE (Gyre Therapeutics Inc) - Profit before payment of interest, taxes and amortization|ASMB (Assembly Biosciences Inc) - Operating profit EBITDA|Profit before interest, taxes and amortization Galectin GALT|Profit before payment of interest, taxes and amortization Genfit S.A. (GNFT)|DRRX (durect.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA ALGS (Aligos Therapeutics, Inc.)|BIVI: Operating profit before amortization|GLMD: Operating profit before deduction of amortization|Profit before interest, taxes and amortization ENDRA Corp|hepionpharma.com (HEPA) - Profit before payment of interest, taxes and amortization